Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Guangdong Bawei Biotechnology Cash Conversion Cycle Related Terms
Guangdong Bawei Biotechnology Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BJSE:920123 vs PG, CL, EL: Cash Conversion Cycle Comparison
For the Household & Personal Products subindustry, Guangdong Bawei Biotechnology's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guangdong Bawei Biotechnology Cash Conversion Cycle vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Guangdong Bawei Biotechnology's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Guangdong Bawei Biotechnology's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guangdong Bawei Biotechnology (BJSE:920123) has a Cash Conversion Cycle of 26.07 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Guangdong Bawei Biotechnology and its competitors.
Is Guangdong Bawei Biotechnology's Cash Conversion Cycle too high?
Guangdong Bawei Biotechnology's current Cash Conversion Cycle is 26.07. The Consumer Packaged Goods industry median Cash Conversion Cycle is 74.74. Guangdong Bawei Biotechnology's value of 26.07 is 65.1% below this industry median. Overall, Guangdong Bawei Biotechnology has a GF Score™ of 42/100, reflecting its overall financial health beyond just this single metric.
How does Guangdong Bawei Biotechnology's Cash Conversion Cycle compare to PG and CL?
Guangdong Bawei Biotechnology's Cash Conversion Cycle of 26.07 can be compared against companies in the Consumer Packaged Goods industry. The industry median Cash Conversion Cycle is 74.74. Guangdong Bawei Biotechnology's value of 26.07 is 65.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Consumer Packaged Goods company?
The median Cash Conversion Cycle among Consumer Packaged Goods companies is 74.74, based on 1,956 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Guangdong Bawei Biotechnology's current Cash Conversion Cycle of 26.07 is 65.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Guangdong Bawei Biotechnology and its competitors. For the Consumer Packaged Goods industry, the median Cash Conversion Cycle is 74.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Guangdong Bawei Biotechnology's current Cash Conversion Cycle is 26.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Guangdong Bawei Biotechnology stock overvalued right now?
Guangdong Bawei Biotechnology (BJSE:920123) has a current Cash Conversion Cycle of 26.07. The current Cash Conversion Cycle is 26.07 and 65.1% below the Consumer Packaged Goods industry median of 74.74. Guangdong Bawei Biotechnology's overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Guangdong Bawei Biotechnology (BJSE:920123), the current Cash Conversion Cycle is 26.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920123 has been successfully added to your 
